UCB agreed to license Antengene’s preclinical CD19xCD3 bispecific T‑cell engager ATG‑201 in a deal with up to $1.1 billion in milestones and roughly $80 million up front. Under terms Antengene will complete first‑in‑human studies and then transfer global rights to UCB for further development and commercialization. ATG‑201 targets B‑cell driven autoimmune diseases using a 2+1 bivalent design intended to improve activity at low target expression. The transaction marks UCB’s entry into the TCE modality for immunology and reflects broader industry momentum to repurpose potent oncology modalities for autoimmune indications.